Diagnostic value of galactomannan in tracheobronchial aspirate for Aspergillus infection in lung transplant recipients (the GALACTBAS study)
Authors:
- Arnau MonforteAMArnau Monforte
- Maria Teresa Martín-GómezMMMaria Teresa Martín-Gómez
- Cristina BerasteguiCBCristina Berastegui
- Anna Falcó-RogetAFAnna Falcó-Roget
- Gonzalo EscuderoGEGonzalo Escudero
- Cristina Kirkegaard-BioscaCKCristina Kirkegaard-Biosca
- Berta Sáez-GiménezBSBerta Sáez-Giménez
- Víctor MonforteVMVíctor Monforte
Open Access
- 10 June 2026
- journal article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 64 (6) , e0155625
Abstract
Lung transplant recipients (LTR) are highly susceptible to Aspergillus infection (AI), but diagnosis may be limited by the invasiveness of bronchoalveolar lavage fluid (BALF) collection. Proximal airway samples may provide a less invasive alternative. We conducted a retrospective single-center study including all adult LTR (March 2018–March 2022) who underwent bronchoscopy with tracheobronchial aspirate (TBA) and BALF galactomannan (GM) testing in the same procedure. They were processed for mycological culture and EIA-based GM (Bio-Rad) after cysteine homogenization. AI was defined according to ISHLT consensus. A ROC curve for TBA GM and its diagnostic performance were assessed. A total of 545 paired TBA–BALF samples from 282 LTR were analyzed. Proven or probable AI was diagnosed in 22 samples (4%). The optimal TBA GM cut-off was ≥0.54 optical density index (ODI), yielding 95.2% sensitivity, 92% specificity, and an AUC of 0.97 (95% CI, 0.95–0.99). In comparison, BALF GM at ≥1.0 ODI showed 33.3% sensitivity and 99.6% specificity (AUC 0.88, 95% CI, 0.80–0.95) although BALF GM values were significantly higher in invasive infections compared with non-invasive infections (1.49 vs 0.14; P -value = 0.007). TBA cultures were more frequently positive than BALF (24% vs 9.9%). Finally, TBA and BALF GM values demonstrated moderate correlation ( r = 0.54), and combined testing with concordant results improved accuracy to 99.6%. TBA GM demonstrated higher sensitivity than BALF GM for detecting AI in LTR, while maintaining high specificity. Proximal airway samples could complement BALF in future diagnostic strategies. IMPORTANCE: This study provides evidence that galactomannan antigen testing (GM) in tracheobronchial aspirate (TBA) is a highly sensitive, reliable, and less invasive diagnostic tool for detecting Aspergillus infection in lung transplant recipients under universal antifungal prophylaxis, compared to the current standard bronchoalveolar lavage fluid (BALF) GM. These findings highlight the diagnostic value of proximal airway specimens, consistent with the pathophysiology of post-transplant aspergillosis, which often originates in the bronchial tree and may not be adequately captured by BALF early in the disease course. Importantly, the study shows that combining TBA and BALF GM results yields near-perfect diagnostic accuracy, supporting a complementary diagnostic strategy rather than a replacement approach. Although this is a proof-of-concept study, it fills a critical evidence gap in transplant infectious diseases and lays the groundwork for safer, more accurate, and earlier diagnosis of Aspergillus infection, with potential implications for clinical practice, antifungal stewardship, and future guideline development.Keywords
Funding Information
- Merck & Co. | MSD Sharp and Dohme (PR(AG)54-2020)
This publication has 32 references indexed in Scilit:
- Beyond guidelines: what do I need to know when dealing with fungal diagnostics?Clinical Microbiology and Infection, 2025
- Performance of the galactomannan test for the diagnosis of invasive pulmonary aspergillosis using non-invasive proximal airway samplesJournal of Infection, 2024
- Lymphadenitis caused by Purpureocillium lilacinum in a patient with CARD9 deficiencyMedical Mycology Case Reports, 2023
- Performance of galactomannan testing from endotracheal aspirate to guide bronchoalveolar lavage in the diagnosis of invasive aspergillosisInfection, 2023
- Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guidelineClinical Microbiology and Infection, 2018
- Airway Complications After Lung TransplantationClinics in Chest Medicine, 2017
- The 2015 International Society for Heart and Lung Transplantation Guidelines for the management of fungal infections in mechanical circulatory support and cardiothoracic organ transplant recipients: Executive summaryThe Journal of Heart and Lung Transplantation, 2016
- Galactomannan detection in bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in patients with hematological diseases—the role of factors affecting assay performanceInternational Journal of Infectious Diseases, 2011
- A 2010 working formulation for the standardization of definitions of infections in cardiothoracic transplant recipientsThe Journal of Heart and Lung Transplantation, 2011
- Cross-reactivity of non-Aspergillus fungal species in the Aspergillus galactomannan enzyme immunoassayDiagnostic Microbiology and Infectious Disease, 2007